The RSP solution

RSP’s technology is based on a direct optical detection principle, Raman spectroscopy. It is a mature technology to which RSP has developed and patented severe improvements. These improvements enables measurement of concentrations of various substances in the interstitial fluid non-invasively through the skin. (Tissue fluid surrounding the cells of the body) .

Proof-of-concept for glucose monitoring on diabetics has been demonstrated through pilot trials in collaboration with Odense University Hospital.

We believe that only Raman spectroscopy offers the option for the direct, non-invasive measurement of concentrations of particular molecules in blood or tissue attributable to its high specificity ( ability to discriminate between different types of molecules).

Raman Spectroscopy

Raman spectroscopy relies on laser lights of a given wavelength (“colour”) hitting a molecule. Hereafter a small fraction of the incident light will interact with the vibrational or rotational states of the molecule. This causes the light particles to lose a portion of their energy, and thereby make the light to change wavelength.


Each molecule species rises a set of possible shifts of the wavelength, thus constituting a spectral “fingerprint” for the molecule. Therefore, by analyzing the scattered light from a sample, one can identify and quantify the molecules contained in the sample. This technique is called Raman spectroscopy.

Raman technology for non-invasive glucose monitoring

Intellectual Property

RSP has researched the field to make Raman spectroscopy capable of non-invasive measurement of relevant molecules in human tissue. The RSP team has spent nine years of R&D and pre-clinical studies to refine Raman technology. That is, the team has further developed the optical system, electronics, data analysis algorithms, as well as know-how of in-vivo measurements required to:

  • Selectively and efficiently collect Raman signal from the interstitial fluid and cells
  • Analyze spectral data to derive the concentration of a given molecule
  • Build a calibration model and use it for deriving concentration values from measurements

Noteworthy, RSP has in the process discovered and patented fundamental aspects of Raman detection of glucose or other substances in human tissue, which removes the dependence of signal calibration on probe position, allowing for unprecedented performance of the method.

Scalable platform technology

RSP’s technology has the potential to enable a number of applications within self-monitoring of health parameters as well as lifestyle management. As an example, elite athletes often use invasive lactate measurement for the detection of their lactate threshold. This is considered the most efficient method for testing of athletic endurance performance. With a non-invasive device, lactate measurement will become convenient and pain-free. Furthermore it’s likely to find widespread use as part of the general trend in society of increased self-tracking in connection with sports and exercise.

RSP is currently focusing on non-invasive glucose monitoring in order to demonstrate the capabilities of the technology, while filling an unmet medical need representing an enormous market opportunity.

Leveraging on the experience and technology from glucose testing devices,  development and commercialization of non-invasive monitoring devices for other applications (e.g. lactate, urea, or cholesterol) will subsequently be faster and less resource demanding.